Brenda Libby Coleman

Array ( [id] => 19379445 [patent_doc_number] => 20240269315 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-08-15 [patent_title] => DRUG CONJUGATE AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 18/566371 [patent_app_country] => US [patent_app_date] => 2022-06-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 33000 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 15 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18566371 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19104619 [patent_doc_number] => 11957692 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-04-16 [patent_title] => Clomipramine for the treatment of Alzheimer's Disease [patent_app_type] => utility [patent_app_number] => 17/751613 [patent_app_country] => US [patent_app_date] => 2022-05-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 33 [patent_no_of_words] => 8813 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 69 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17751613 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19816782 [patent_doc_number] => 20250074989 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-03-06 [patent_title] => METHODS AND COMPOSITIONS FOR TREATING PANCREATIC DISEASE [patent_app_type] => utility [patent_app_number] => 18/561199 [patent_app_country] => US [patent_app_date] => 2022-05-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25623 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -115 [patent_words_short_claim] => 90 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18561199 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17851790 [patent_doc_number] => 20220281832 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-09-08 [patent_title] => CRYSTAL MODIFICATIONS OF ODEVIXIBAT [patent_app_type] => utility [patent_app_number] => 17/744429 [patent_app_country] => US [patent_app_date] => 2022-05-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20280 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 63 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17744429 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20179470 [patent_doc_number] => 20250263428 [patent_country] => US [patent_kind] => A2 [patent_issue_date] => 2025-08-21 [patent_title] => AMIDE-LINKED CONJUGATE COMPOUNDS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/725689 [patent_app_country] => US [patent_app_date] => 2022-04-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12162 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 228 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17725689 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18964149 [patent_doc_number] => 11897899 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-02-13 [patent_title] => Nitrogen-containing condensed ring compounds having dopamine D3 antagonistic effect [patent_app_type] => utility [patent_app_number] => 17/726153 [patent_app_country] => US [patent_app_date] => 2022-04-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 65546 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 1253 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17726153 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20179470 [patent_doc_number] => 20250263428 [patent_country] => US [patent_kind] => A2 [patent_issue_date] => 2025-08-21 [patent_title] => AMIDE-LINKED CONJUGATE COMPOUNDS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/725689 [patent_app_country] => US [patent_app_date] => 2022-04-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12162 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 228 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17725689 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18251474 [patent_doc_number] => 20230078513 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-03-16 [patent_title] => INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/724753 [patent_app_country] => US [patent_app_date] => 2022-04-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 153410 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 574 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17724753 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19225433 [patent_doc_number] => 12005063 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-06-11 [patent_title] => Medicament for preventing and/or treating dry eye [patent_app_type] => utility [patent_app_number] => 17/722947 [patent_app_country] => US [patent_app_date] => 2022-04-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 4 [patent_no_of_words] => 5626 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 25 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17722947 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19263506 [patent_doc_number] => 20240207203 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-06-27 [patent_title] => NOVEL USE [patent_app_type] => utility [patent_app_number] => 18/555095 [patent_app_country] => US [patent_app_date] => 2022-04-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4605 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 16 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18555095 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19586312 [patent_doc_number] => 20240383869 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-11-21 [patent_title] => ARYLACETYL INHIBITORS OF TG2 AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/554358 [patent_app_country] => US [patent_app_date] => 2022-04-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 27389 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18554358 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20335276 [patent_doc_number] => 20250339396 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-11-06 [patent_title] => NOVEL MODULATORS OF THE MELATONIN RECEPTORS AS WELL AS METHOD OF MANUFACTURE AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/554353 [patent_app_country] => US [patent_app_date] => 2022-04-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 29744 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -28 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18554353 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19187735 [patent_doc_number] => 20240166648 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-05-23 [patent_title] => Novel Crystalline Form Of 1-(8-Bromopyrido[2,3-E][1,2,4]triazolo[4,3-A]pyrazin-4-Yl)-Nmethylazetidin-3-Amine Hydrogen Sulfate Monohydrate [patent_app_type] => utility [patent_app_number] => 18/283916 [patent_app_country] => US [patent_app_date] => 2022-03-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5931 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18283916 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19472566 [patent_doc_number] => 12102628 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-10-01 [patent_title] => Composition and methods for the treatment of myopia [patent_app_type] => utility [patent_app_number] => 17/706225 [patent_app_country] => US [patent_app_date] => 2022-03-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10851 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 72 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17706225 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19403588 [patent_doc_number] => 20240287099 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-08-29 [patent_title] => 1,4-Sulfur-Bridged Polycyclic Compounds Containing Dihydrobenzofuran Structure, Its Preparation Method and Application Thereof [patent_app_type] => utility [patent_app_number] => 17/786470 [patent_app_country] => US [patent_app_date] => 2022-03-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5598 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 75 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17786470 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18102422 [patent_doc_number] => 11542297 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-01-03 [patent_title] => Compositions and methods for treating CNS disorders [patent_app_type] => utility [patent_app_number] => 17/695033 [patent_app_country] => US [patent_app_date] => 2022-03-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 54618 [patent_no_of_claims] => 28 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 34 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17695033 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17720417 [patent_doc_number] => 20220213137 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-07-07 [patent_title] => COMPOSITIONS AND METHODS FOR TREATING CNS DISORDERS [patent_app_type] => utility [patent_app_number] => 17/694896 [patent_app_country] => US [patent_app_date] => 2022-03-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 54609 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -28 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17694896 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19871293 [patent_doc_number] => 12264137 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-04-01 [patent_title] => 3-aryl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors [patent_app_type] => utility [patent_app_number] => 17/691186 [patent_app_country] => US [patent_app_date] => 2022-03-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18783 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 782 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17691186 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19012953 [patent_doc_number] => 11919868 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-03-05 [patent_title] => Heterocyclic compounds and related methods [patent_app_type] => utility [patent_app_number] => 17/684352 [patent_app_country] => US [patent_app_date] => 2022-03-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28453 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 16 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17684352 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18093055 [patent_doc_number] => 20220411396 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-12-29 [patent_title] => TRIOXOLANE AGENTS [patent_app_type] => utility [patent_app_number] => 17/680825 [patent_app_country] => US [patent_app_date] => 2022-02-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 63872 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17680825 [rel_patent_id] =>[rel_patent_doc_number] =>)